Two-Year Agility Maintenance Training Slows the Progression of Parkinsonian Symptoms by Tollár, József et al.
D
ow
nloaded
from
http://journals.lw
w
.com
/acsm
-m
sse
by
B
hD
M
f5eP
H
K
bH
4TTIm
qenV
D
iE
otxS
R
1U
H
dqW
TH
P
m
+4jaR
m
rV
H
S
zaH
uW
3aew
0dyG
8U
S
pkW
vK
M
5C
4M
=
on
10/10/2018
Downloadedfromhttp://journals.lww.com/acsm-mssebyBhDMf5ePHKbH4TTImqenVDiEotxSR1UHdqWTHPm+4jaRmrVHSzaHuW3aew0dyG8USpkWvKM5C4M=on10/10/2018
 
. . . Published ahead of Print 
 
 
 
Medicine & Science in Sports & Exercise® Published ahead of Print contains articles in unedited 
manuscript form that have been peer reviewed and accepted for publication. This manuscript will undergo 
copyediting, page composition, and review of the resulting proof before it is published in its final form. 
Please note that during the production process errors may be discovered that could affect the content. 
 
Copyright © 2018 American College of Sports Medicine 
Two-Year Agility Maintenance Training Slows the Progression 
of Parkinsonian Symptoms 
 
 
József Tollár
1
, Ferenc Nagy
1
, Norbert Kovács
2,3
, and Tibor Hortobágyi
4
 
 
1
Somogy County Kaposi Mór Teaching Hospital, Kaposvár, Hungary 
2
Department of Neurology Clinic, University of Pécs, Hungary 
3
MTA-PTE Clinical Neuroscience MR Research Group, Pécs, Hungary 
4
University of Groningen, University Medical Center Groningen, The Netherlands 
 
 
 
 
Accepted for Publication: 19 September 2018 
AC
CE
PT
ED
 Two-Year Agility Maintenance Training Slows the Progression of 
Parkinsonian Symptoms 
 
 
József Tollár
1
, Ferenc Nagy
1
, Norbert Kovács
2,3
, and Tibor Hortobágyi
4
 
 
 
1
Somogy County Kaposi Mór Teaching Hospital, Kaposvár, Hungary  
2
Department of Neurology Clinic, University of Pécs, Hungary 
3
MTA-PTE Clinical Neuroscience MR Research Group, Pécs, Hungary 
4
University of Groningen, University Medical Center Groningen, The Netherlands 
 
 
Corresponding author: József Tollár, Somogy County Kaposi Mór Teaching Hospital, 
Kaposvár, Tallián Gyula street 20-32, H-7400, Hungary. Email: tollarjozsef86@gmail.com  
 
The study was registered as a clinical trial (NCT03189680). 
 
Supported in part by the Department of Neurology, Somogy County Moricz Kaposi General 
Hospital, and by a ‘Regional Health Development’ award from the Doctoral School of the 
Faculty of Health Sciences, University of Pécs. 
Medicine & Science in Sports & Exercise, Publish Ahead of Print 
DOI: 10.1249/MSS.0000000000001793
Copyright © 2018 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
The authors declare no conflict of interest. The authors state that the results of the study are 
presented clearly, honestly, and without fabrication, falsification, or inappropriate data 
manipulation. 
 
The present study does not constitute endorsement by ACSM.  
Copyright © 2018 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
Abstract 
 
Introduction — Parkinson’s disease (PD) is a progressive neurodegenerative condition and it is 
unclear if long-term non-pharmaceutical interventions can slow the progression of motor and 
non-motor symptoms and lower drug dose. 
 
Methods — In a randomized trial, after an initial 3-week-long, 15-session supervised high-
intensity sensorimotor agility exercise (E) program designed to improve postural instability, the 
Exercise+Maintenance (E+M, n=19) group continued to exercise three times per week for 2 
years, while E (n=16) and the no exercise and no maintenance control (C, n=20) continued 
habitual living. Eight outcomes were measured before and after the 3-week initial exercise 
program and then at 3, 6, 9, 12, 18, and 24 months in all patients. 
 
Results — The Group by Time interactions (all p<0.005) revealed robust and favorable effects 
of the initial 3-week agility program on all 6 non-motor (e.g., primary outcome MDS-UPDRS- 
M-EDL: ~7 points; EuroQoL: ~9 points) and on each of the 2 motor outcomes (timed up and go 
test: ~6 s; posturography: up to 7 mm improvements in center of pressure path). E+M maintained 
but did not further improve the benefits produced by the initial 3-week program. In E, the 
favorable effects of the 3-week agility program lasted for 3 to 12 months. In C, patients declined 
steadily in all outcomes over 2 years. By year 2, Leva-dopa equivalents increased by 99.4 
mg/day (Time main effect, p = 0.008). 
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Conclusion: A high-intensity sensorimotor agility program with but not without a 2-year 
maintenance program slowed the progression of parkinsonian symptoms. 
 
Key words: follow up, sensorimotor training, balance training, posture, quality of life 
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Introduction 
Parkinson’s disease (PD) is associated with a decline in postural control, walking ability, an 
increased risk for falling, and a deteriorating quality of life (1-3). While pharmacological 
treatments are still the mainstream to treat motor symptoms, physical exercise can also improve 
PD patients’ postural control and mobility (2-6). Recommendations urge the use of high intensity 
exercise stimulus to produce rapid and lasting improvements in PD symptoms (4,7,8). However, 
the results are inconsistent. Even at the same disease stage, treadmill exercise improved gait 
speed and cardiovascular fitness independent of exercise intensity (9). In addition, high 
compared with low frequency exercise can unfavorably affect functional outcomes (10). Yet 
there is also evidence that exposing PD patients to high-intensity exercising training can 
functionally meaningfully improve early-stage PD patients’ symptoms (8). How long such 
exercise effects last after the exercise stimulus is withdrawn is also unclear. Despite 
recommendations to measure the effects at least for 24 months, in 16 studies the average follow-
up time was 5.5 months (2,5). The only study with a 24-month-long maintenance program 
reported favorable effects on selected motor symptoms but also numerically almost identical 
elbow flexion torque at baseline (50.8 Nm) and at 24 months (50.2 Nm) (11). Yet a second 
booster dose of multidisciplinary intensive rehabilitation exercise at Year 1 after an initial bout at 
baseline even without a maintenance program, improved, at Year 2, UPDRS III scores, 6-minute 
walking distance, and timed up and go performance by 3.4 points, 41.1 m, and 1.1 s, respectively 
(12).  
 
Whether exercise can reduce patients’ drug dose is unclear. In one case, L-dopa equivalent 
increased moderately by 38.4% in the intensive exercise group compared with 327.4% in the no-
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exercise controls at the end of the 2-year follow-up period, suggesting that intense exercise 
without a maintenance program could moderate drug dose (12). Despite the 2-year low-intensity 
exercise maintenance program, L-dopa equivalent, however, still increased by 29% (11). It is 
thus unclear if a high-intensity and long-term exercise maintenance program could reduce the 
increase normally seen in PD patients’ medication.  
 
The purpose of the present study was to determine the immediate and long-term effects of a 3-
week-long, high-intensity and high-frequency agility program on PD patients’ motor and clinical 
symptoms with and without a 2-year-long high-intensity agility maintenance program. We 
expected that patients would tolerate the short-term 3-week initial high-intensity agility program 
and motor and non-motor symptoms would improve and that the maintenance program would 
sustain these improvements and slow the progression of symptoms. Based on previous studies 
(11,12), we also expected that the maintenance program would slow the increase in L-dopa 
equivalent levels. 
 
Methods 
Design and patients. This is a three-group, randomized clinical trial involving PD patients who 
met the UK Brain Bank criteria and were of stages 2-3 on the Hoehn and Yahr scale. Fig. 1 
shows the Consort diagram. Form the hospital database and the outpatient clinic we identified 72 
patients who met inclusion criteria based on medical records. Of these, 17 were excluded and the 
remaining 55 randomized into: Exercise+Maintenance (E+M, n=19, 11M); Exercise only group 
(E, n = 16, 6M), and to a no exercise and no maintenance control group (C, n=20, 12 M; Table 
1). At the time of the start of the study and for a two-year period preceding it, none of the 
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patients were enrolled in rehabilitation. The initial high-intensity and high-frequency agility E 
program lasted three weeks. The M program lasted two years. All patients were assessed eight 
times: before and after the 3-week exercise program and at 3, 6, 9, 12, 18, and 24 months. Wait-
listed patients in C had the opportunity to enroll in the exercise program after the end of the trial. 
After the 3-week initial exercise intervention, patients in E and C were not enrolled in an 
exercise or maintenance program during the two-year period. 
 
Patients were recruited from the hospital database. An initial screening established disease 
severity by the language-validated version of Movement Disorder Society Unified Parkinson 
Disease Rating Scale, Motor Experiences of Daily Living (MDS-UPDRS-M-EDL). A 
preliminary screening included a full neurological exam and a mobility evaluation. The exam 
ensured that all included patients had mobility difficulty and postural instability based on a 
qualitative assessment of gait and postural stability, turns, rigidity, inter-joint coordination, trunk 
posture, and equilibrium while subjects walked forward, backwards, and sideways. In a separate 
visit, a neuropsychologist evaluated patients’ cognitive function. Patients were excluded with 
brain abnormalities based on a diagnostic MRI, Mini Mental State Examination score <24, a 
Beck Depression Inventory score >40, severe cardiac disease, uncontrolled diabetes, a history of 
stroke, traumatic brain injury, seizure disorder, past or current deep brain stimulation, or current 
participation in a self-directed or formal group exercise program. All patients remained ‘on’ 
medication so that the assessments at baseline and after the intervention and each exercise 
session occurred 1-2h after patients took PD medications.      
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The principal investigator performed the randomization. He drew a colored ribbon from a 
covered box and attached one ribbon to each patient’s folder (E: red, E+M: blue, C: green). Two 
physical therapists and a physical therapy assistant administering the tests, were masked to 
patients’ group assignments. In the familiarization session patients practiced each test and 
watched the Xbox kinect programs, a key element of the intervention. Patients gave written 
informed consent to participate in the study. The University Hospital’s Ethics Committee (IKEB) 
approved the study protocol. The trial was registered at Clinicaltrials.gov (NCT03193489). 
 
Outcome measures. The primary outcome was MDS-UPDRS-13 M-EDL, which is sensitive to 
changes in a broad spectrum of PD symptoms (13). We accepted changes >3.1 points as a 
minimal clinically important difference (14). The lead physical therapist administered this test in 
person every time to every patient to assess motor signs of PD. 
 
Secondary outcomes measured changes in HRQoL using: 1) Schwab and England Activities of 
Daily Living Scale (ADL); 2) EuroQol EQ-5D, and 3) the Parkinson’s Disease Questionnaire 
(PDQ-39, minimal clinically important difference: 4.7 points) (15). The Beck Depression 
Inventory measured depression and the timed up and go test (TUG) quantified mobility. We 
quantified postural stability by the magnitude of sway measured on a force platform while 
standing in a wide and a narrow stance with eyes open or closed. Participants stood for 20 s in 
each of the four conditions administered in order of: 1) eyes open wide and 2) narrow stance 
followed by standing with eyes closed 3) in a wide and 4) in a narrow stance. The outcome was 
the 3D path of the center of pressure (in mm). The testing order was standardized among patients 
and testing sessions. Adverse events were not systematically assessed.  
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Intervention. The Exercise program comprised a high-intensity agility intervention, detailed 
previously in the supplementary material of that paper comprising a different group of patient 
(16). Briefly, E+M and E completed 15, 1-h-long, sessions over 3 weeks and targeted deficits in 
postural control and mobility. Three therapists delivered the program by having patients exercise 
in small groups at individual times only in the hospital’s physical therapy gym. Therapists 
demonstrated most exercises, mingled among patients on the exercise floor to closely supervise 
and spot them for safety. Patients were asked not to enroll in any other activity programs and 
perform additional exercises at home on their own.  Patients exercised without shoes on a 26-mm 
thick Theraband-carpeted floor. After 10 minutes of warm-up, patients completed a 20-minute 
block of sensorimotor and visuomotor agility training and a 20-minute block of sensorimotor 
agility training using the X-box virtual reality exergame (Microsoft xbox 360 core system with 
kinect, Microsoft Corp.) (17). Each session ended with 10 minutes of cool down. The 
sensorimotor and visuomotor agility training included: 1) gait training, 2) coordination training, 
3) posture training with and without an augmented sensory input, 4) balance exercises with and 
without a peer, assistive devices, height stimuli, surface modifications, postural changes, shifts 
between tasks, and directional changes, 5) body scheme exercises, and 6) posture-corrective 
exercises. We detailed previously exercise dosing, surface manipulations, task numbers, task 
types, feedback, and other methods to increase and manipulate motor and sensory stimuli, 
including the sophisticated use of the X-box virtual reality exergame and how patients kept an 
exercise log to record symptoms, fatigue, and attendance. A video clip in Supplement 1 shows 
patients exercising (see Video, Supplemental Digital Content 1, PD patients performing 
exergaming agility exercises, http://links.lww.com/MSS/B403). The non-Exergaming and 
Exergaming each represented about 50% of the total exercise time. The average heart rate and 
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rate of perceived exertion was 120.6 beats per minute and 13.6 or about 80% age-predicted 
maximum heart rate and ’somewhat hard / hard’ on the 20-point Borg scale (unpublished data). 
 
Maintenance program. After the 3-week-long, daily, high-intensity Exercise intervention, E+M 
continued the Maintenance program three times per week for two years in the hospital’s physical 
therapy gym using the same exercises used in the 3-week-long initial exercise program. The 
three therapists supervised each session attended by small groups of 3-5 patients who exercised 
at the same time of the day for 1 h. The aim of the maintenance program was to determine if 
patients can endure a high-intensity rehabilitation program for an extended time period and if 
such a program can slow disease progression. E did not perform the maintenance phase and C 
received no Exercise therapy and no Maintenance either. 
 
Statistical analyses. We estimated the number of participants needed for a significant Group 
(E+M, E, C) by Time (0 and 3wk, 3, 6, 9, 12, 18, 24 months) analysis of variance with repeated 
measures on Time for a change of 4 points caused by the initial intense intervention (>3.1 
functionally meaningful change) (14). Using an alpha of 0.05, 1- beta (power) of 0.8, 3 groups, a 
correlation of 0.5 between repeated measures, the total sample size needed was 49 patients. 
Anticipating dropouts, we randomized 55 patients.  
 
Data are expressed as mean ±SD. The variables were normally distributed based on the Shapiro–
Wilk test. The main analysis was a Group (E+M, E, C) by Time (0 and 3wk, 3, 6, 9, 12, 18, 24 
months) analysis of variance with repeated measures on Time. In case of an interaction, we used 
a Tukey’s post-hoc contrast to determine the means that differed at p<0.05. We also compared at 
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baseline those nine patients who deceased over the two years with those who completed the trial. 
We computed Pearson correlations between changes in the primary and secondary outcomes to 
explore potential mechanistic links underlying improvements in patients’ mobility and clinical 
symptoms. The level of significance was set at p<0.05. All statistical analyses were conduced 
with SPSS version 22. 
 
Results 
Table 1 shows that the groups were similar at baseline. During the 3-week high-frequency 
exercise program and also during the 2-year-long maintenance program, attendance and 
compliance were 100%, dropout was 0%, and there were no adverse events, which were not 
assessed systematically. 
 
Primary outcome. The 3-week-long agility program improved MDS-UPDRS M-EDL 
significantly (p < 0.05) but similarly by 30.4% (±10.23) or 6.3 points (±3.06) in E+M and by 
42.8 % (±9.43) or 7.8  (±1.57) points in E. These changes were greater than the non-significant 
changes in C (Group by Time interaction, F12,258=32.7, p=0.001, Table 2, Figure 2A).  
 
E+M sustained the exercise-induced benefits. In E, the exercise-induced improvements were still 
present at 3 months. C exhibited a gradual worsening over the two years. At year 2, there was a 
12.4 points difference in favor of E+M vs. C (p<0.05). Over two years, the MDS-UPDRS M-
EDL score had decreased by 6 points in C.  
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Secondary outcomes. The Group by Time interaction for L-Dopa equivalents was not significant 
(p=0.662) and the dose increased by 97.4 mg/day or 11.4% in the three groups combined (Time 
main effect), F4,168=3.6, p=0.008 (Figure 3.) 
 
The agility program improved the PDQ by 26.0% (±7.36) in E+M and by 28.9% (±9.31) in E, 
more than the  6.8% (±16.85) worsening in C (interaction, F12,258=9.9, p=0.001, Table 2, 
Figure 2B). E+M kept the exercise-induced improvements in PDQ for two years at a steady 
level. In E, the exercise effects were still present at 12 month (Figure 2B). At 24 months, E+M 
vs. E and E+M vs. C had 15.3 and 24.4 points better PDQ score (both p<0.05). E still had a 9.1 
better score than C (p<0.05). Over the two years, the PDQ score had decreased by 20 points in C 
(Table 2). 
 
The exercise intervention improved the Beck Depression Index (F12,258=12.5), the Schwab and 
England ADL inventory (F12,258=8.9), the EQol VAS scores (F12,258=10.3), and the EQoL 
summed scores (F12,258=21.5) in E+M (range of improvements: 13% to 21%, all p ≤ 0.001) and 
in E (14% to 20%, all p<0.05, Table 2). In E, these effects lasted for three months. At 24 months, 
E+M still showed the exercise-induced gains and E returned to baseline. Compared with E+M at 
24 months, the scores in C were all worse in the Beck Depression Index, Schwab and England 
ADL inventory, the EQol VAS scores and in the EQoL summed scores(all p<0.05). 
 
TUG improved by 6.3 s (±2.75) in E+M and by 6.0 s (±2.96) E (all p<0.05) compared with the 
0.6 s (±0.76) in C (n.s.) (interaction, F12,258=20.2, p<0.001, Table 2, Figure 2C). These effects 
lasted for 18 months in E (Figure 2C). At 24 months, E+M had 6.8 s shorter TUG time than C 
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(p<0.05). TUG remained unchanged over two years in C (n.s.). Exercise decreased COP path in 
the four conditions similarly in E+M and E (range: 2.0 to 6.9 mm) and E+M sustained the 
exercise-induced improvements. In E, the exercise effects lasted until month 12 in the four 
posturography measures. At 24 months, E+M vs. E had 4.7 to 2.5 mm shorter COP path in the 
four measures (p<0.05) and these differences between E+M vs. C had even larger (range: 4.2 to 
6.7 mm, p<0.05).  
 
Correlation analyses. MDS-UPDRS M-EDL at baseline correlated with the change in MDS-
UPDRS M-EDL at 3 weeks r=-0.803 and this correlation essentially remained unchanged by 24 
months (r =-0.683, n=18, p< 0.05). Because the primary outcome reached a plateau at month 3 
during follow up in E+M (n=18, Figure 2A), we determined the relationship between changes in 
the primary outcome, MDS-UPDRS M-EDL, for the period from baseline to 3 month and the 
changes over the same period in PDQ (r=0.422), Beck depression score (r=0.198), EQ VAS (r=-
0.181), TUG (r=0.126), and the four postural measures (range of r = 0.092 to 0.297). None of 
these correlations were significant (p>0.05). The correlation between changes in MDS-UPDRS 
M-EDL and number of PD years was also low (r=0.271).   
 
Characteristics of deceased patients.  One, three, and five patients, respectively, died in E+M, E, 
and C, with 46 of 55 original patients completing the 2-year study. Causes of death were heart 
attack (n=2), unknown (n=3), tumor (n=2), and stroke (n=2), all unrelated to study. Table 3 
shows the baseline comparisons between patients who died and those who were alive at the end 
of the 2-year program. At baseline, there were differences between these two groups in MDS-
UPDRS M-EDL and TUG. 
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Discussion 
High-intensity and high-frequency supervised sensorimotor agility exercise (3wks, 15 sessions) 
improved PD patients’ motor and non-motor symptoms. The subsequent 2-year-long supervised 
maintenance program sustained but did not further improve the benefits produced by the initial 
3-week program in the eight outcomes. The favorable effects of the 3-week agility program 
without the maintenance program on motor and non-motor symptoms lasted for 3 to 12 months. 
Patients in the no-intervention control group declined steadily in all outcomes over two years. 
Exercise therapy with and without the maintenance program did not reduce drug dose. 
 
Acute exercise effects 
The data contribute to the emerging picture that a variety of motor interventions can improve PD 
patients’ motor and clinical symptoms (2-5). The ~7.0 points (n=35, effect size 1.2), over twice 
the 3.1 points of clinically meaningful improvements(14) in MDS-UPDRS M-EDL are similar to 
the changes of 7.3 in UPDRS III following a 4-week-long multidisciplinary intensive 
rehabilitation treatment (12). The improvements correlated strongly with the baseline scores, 
suggesting that the intervention was particularly effective and, as hypothesized, not harmful in 
patients with low initial scores. Thus, high-intensity and challenging exercise therapy is effective 
for PD patients with a Hoehn–Yahr stage 1.2 (12) but also for patients at stage of 2-3 (present 
study, Table 1) to improve perceived and measured mobility, posture, and clinical symptoms. 
Future studies will determine whether or not high intensity and frequency are prerequisites to 
induce such acute effects on MDS-UPDRS M-EDL, as lower intensity yoga, dance, and balance 
training are also effective(2-5) and superior to very low intensity physical and occupational 
therapy (18).  
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The 3-week-long intervention uniformly improved secondary outcomes of perceived and 
objectively measured functions by 13 to 55% (effect sizes: 0.53-2.54, Table 2). Because 
depression affects quality of life most, it was important to see that exercise improved QoL and 
the Beck Depression Index (3.3 points). Thus, agility training in addition to aerobic exercise can 
also improve PD patients’ depression (19,20). Changes in the Schwab and England (10 points), 
TUG (6.1 s), PDQ (13.3 points) and posturography scores suggest improved static and dynamic 
balance and non-motor symptoms, confirming and for the most part exceeding changes reported 
previously (2-5) The high response rate in all outcomes is probably related to the suitability of 
the exercise stimulus, as patients attended all sessions and none dropped out.  
 
Maintenance program 
A 2-year-long agility maintenance program slowed the progression of PD symptoms (Figure 2, 
Table 2). The maintenance program clinically meaningfully (14) further improved the primary 
outcome by 3.5 points at Month 3 but thereafter this improved level remained unchanged. The 
favorable initial rapid adaptations to the 3-week program disappeared in E so that at Month 6 
there were no differences (2 points, n.s.) in MDS-UPDRS M-EDL scores between E and C 
(Figure 3, Table 2). The maintenance program did not further increase the gains produced by the 
initial intense exercise phase in the secondary outcomes but the maintenance program was 
necessary to sustain the initial gains in all outcomes. The data provide evidence that even short-
term exercise programs can moderate PD patients’ motor and non-motor symptoms. However, 
such changes are transient and for lasting neuroprotective and restorative effects to occur, PD 
patients need to participate in long-term maintenance programs (1-5,21).  
 
Copyright © 2018 by the American College of Sports Medicine. Unauthorized reproduction of this article is prohibited.
AC
CE
PT
ED
Agility and resistance training can both improve motor and non-motor symptoms and maintain 
such improvements (11,12,22). The difference between our agility and other agility and 
resistance training programs could be in effectiveness. In our patients the MDS-UPDRS M-EDL 
scores were 12.4 points lower (better) than control (Figure 2, Table 2) in contrast to the 2.2-point 
difference reported at Month 24 in favor of the multidisciplinary intensive rehabilitation 
treatment versus control (12). In this study patients’ disease severity was lower (mean Hoehn–
Yahr stage of 1.2) (12) than in the present study (range Hoehn–Yahr stage of 2-3). The on-
medication MDS-UPDRS III scores at Month 24 after resistance training maintenance program 
changed little (11). Taken together, it may be necessary to keep exercise intensity high for a 
prolonged period to slow the progression of PD symptoms and improve MDS-UPDRS M-EDL 
scores by 12.4-point (Table 2). The agility program did not affect drug dose, which, against our 
expectation of a relative reduction, increased by 11% (12).  
 
Most PD patients with a diagnosis of stage 2-3 on the Hoehn-Yahr scale present with multiple 
comorbidities. Those who died compared with those who completed the program differed 
(p<0.05) at baseline only in two variables (MDS-UPDS M-EDL: worse score by 7.2 points; 
TUG: 2.9 s longer; Table 3). The suggestion emerging from these data requires confirmation as 
to which variables could be used to predict progression of PD symptoms in stage 2 to 3 PD 
patients. 
 
The mechanisms of how a prolonged and high-intensity exercise incorporating sensorimotor and 
visuomotor stimuli might slow the progression of disease in PD patients remain unclear. Short-
term intensive balance training challenges postural stability and produced correlated 
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morphometric changes in gray matter of brain areas and balance behavior (23). Motor-cognitive 
training decreased PD patients’ reliance on frontal brain structures, resulting in improved 
functioning (24). At the cellular level, animal and human PET data suggest that exercise can 
improve dopamine signaling, leading to task-specific improvements in postural control (25-27). 
Such improvements in motor function are accompanied by neuroplastic changes, including 
improved dopaminergic signaling through an increase in striatal dopamine release, reduced 
dopamine reuptake, and an elevated dopamine-D2 receptor expression measured at protein and 
transcript levels. Sustained exercise activates neurotrophic factors, which produce anti-
inflammatory and pro-regenerative effects on motor and cognition function in old adults with 
and without a degenerative condition (28-31). In particular, there is emerging evidence 
suggesting that rapid reactive movements to external and internal perturbations on unstable 
surfaces, as done in the present agility training study, could increase the descending neural drive 
leading to correlated improvements in clinical symptoms and in the magnitude, timing and rate 
of torque generation (32). 
 
Limitations, conclusions 
Without a maintenance-only group we cannot tell if the initial 3-week-long exercise period 
enhanced the maintenance effects. It is likely that some of the maintenance effects were due to 
the attention and social contact patients received over the two years in contrast to a lack of 
attention and contact in the E and C groups. The correlations between changes in the outcomes 
did not reach significance, making causation among variables not possible. As the outcomes 
were purely behavioral, we could not examine any potential mechanisms. To achieve and 
maintain the high exercise intensity, adherence, and compliance, three therapists and a 
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designated facility were needed, conditions that may not be available in many settings. Finally, 
without a high-intensity comparison group such as intensive cycling (33,34), in which interaction 
with unstable surfaces and rapid responses to external and internal perturbations are absent, we 
cannot tell if in the present and past studies (4,8,12,32,35) the agility or the fitness stimulus did 
in fact produce the disease-slowing postural and mobility improvements, an issue we are 
addressing in our ongoing studies. A lack of systematic assessment of adverse events is a 
limitation but anecdotally and based on patients’ exercise diaries we found no evidence for 
program-related falls in and outside the gym. The deaths for which pathology reports were 
available were caused by serious medical conditions unrelated to the intervention. In conclusion, 
a high-intensity sensorimotor agility program with but not without a 2-year maintenance program 
slowed the progression of PD patients’ motor and non-motor symptoms without reducing drug 
dose. 
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Supplemental Digital Content  
Supplemental Digital Content 1. Exergaming.avi. PD patients performing exergaming agility 
exercises. Tollár et al, 35 s, 5 MB. 
 
Figure Captions 
Figure 1. Consort diagram. E, Exercise only for three weeks, E+M, Exercise for three weeks 
followed by a Maintenance program for two years, and C, Control, no Exercise and no 
Maintenance.  
 
Figure 2. Effects of a 3-week-long exercise program and a 2-year-long exercise maintenance 
program on measures of parkinsonian symptoms and mobility. Change scores after 3 weeks of 
high-intensity individualized agility training (dark gray shading) with (E+M, n=18, filled circles) 
and without (E, n=13, filled squares) a maintenance exercise program or no exercise and no 
maintenance control (n=13, open circles) on MDS-UPDRS M-EDL (A), PDQ summed scores 
(B), and timed-up-and-go (TUG) test (C) followed by a 24-months-long follow-up period. 
Horizontal thin line denotes baseline above and below which, respectively performance is worse 
and better. Vertical bars denote 1 + or – standard deviation. *, Group by Time interaction (p < 
0.05). a, Control (open symbol) different from the other two groups; 
 
b, All three groups differ from one another; c, Exercise+Maintenance group (filled circles) 
different from Control (open symbols), d, Exercise+Maintenance group (filled circles) different 
from Control (open symbols) and Exercise group (filled squares). 
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Figure 3. Changes in drug dose. Effects of 3 weeks of high-intensity individualized agility 
exercise (E) training with (E+M, n=15, filled circles) and without (E, n=13, filled squares) a 
maintenance agility exercise program or no exercise and no maintenance control (C, n=17, open 
circles) on L-Dopa equivalent dose. Compared with baseline (0wk), the drug dose was ~11% 
higher at Month 24 (24mo) in the three groups combined (Time main effect, p=0.008, not 
graphed). Vertical bars denote + or – 1 standard deviation, omitted for clarity in the Control (C) 
group. 
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Figure 2 
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Figure 3 
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Table 1. Patient characteristics as baseline. 
 
 E+M, n = 19 (11M) E, n = 16 (6M) C, n = 20 (12M) All, n = 55 (29M)  
Variable Mean   ±SD Mean  ±SD Mean ±SD Mean ±SD 
Age, y 67.5 3.91 67.6 3.26 67.6 4.08 67.6 3.75 
Height, cm 173.8 6.56 172.0 4.70 174.6 5.70 173.4 5.66 
Mass, kg 75.4 11.32 73.9 7.0 78.4 11.19 76.0 10.20 
BMI, kg·m
·-2
 24.9 2.65 24.9 1.81 25.7 2.75 25.2 2.46 
PD years 6.5 2.67 6.8 1.76 7.1 2.75 6.8 2.39 
Hoehn - Yahr stage 2.5 0.51 2.31 0.48 2.40 0.50 2.40 0.49 
L-Dopa equivalent, 
mg/day 774.2 381.5 912.6 380.1 884.8 332.0 857.2 364.5 
MDS-UPDRS M-EDL 19.5 6.28 19.1 4.54 18.9 7.94 19.1 6.41 
PDQ-39               
  Mobility 17.9 6.45 15.3 3.57 16.1 9.13 16.5 6.92 
  ADL 6.8 2.81 5.5 1.93 8.1 4.75 6.9 3.56 
  Emotions 6.3 3.11 6.3 2.47 7.1 4.75 6.6 3.60 
  Stigma 5.1 1.90 5.3 1.70 5.7 3.20 5.4 2.38 
  Social 1.5 1.61 2.3 1.57 1.6 1.85 1.7 1.69 
  Cognition 4.6 2.36 5.0 2.13 4.7 3.10 4.7 2.56 
  Communication 2.6 1.92 2.8 2.20 2.7 1.98 2.7 1.99 
  Body pain 4.1 1.87 3.8 1.61 4.6 2.16 4.2 1.91 
  Sum of sub-items 51.1 16.99 49.4 8.73 50.5 25.61 50.4 18.67 
BDI 19.3 5.60 14.4 3.58 18.0 10.60 17.4 7.59 
SE ADL, %* 78.4 11.43 71.2 7.54 68.1 16.20 72.6 11.72 
EQ-5D VAS, mm 64.5 13.73 67.5 8.563 61.1 11.52 64.1 11.69 
EQ-5D                
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   Mobility 2.3 0.54 2.7 0.63 3.5** 0.51 2.5 0.56 
   Self-care 1.6 0.55 2.2 0.51 2.5 0.49 2.1 0.52 
   Usual activities 1.9 0.59 2.1 0.51 2.4 0.67 2.1 0.59 
   Pain 1.8 0.58 2.5 0.54 2.7 0.61 2.3 0.58 
   Anxiety 2.2 0.71 2.2 0.69 2.9 0.61 2.4 0.67 
  Sum of sub-items 14.2 2.43 12.9 1.45 15.05** 2.42 14.1 2.32 
TUG, s 17.0 3.81 15.1 3.31 18.6** 4.18 17.0 4.00 
COP path, mm               
   Wide stance, EO 8.7 7.60 6.3 5.74 7.2 4.21 7.4 5.97 
   Wide stance, EC 9.2 5.44 7.0 2.66 7.2 4.18 7.8 4.37 
   Narrow stance, EO 10.8 6.06 7.3 3.71 8.1 3.75 8.8 4.82 
   Narrow stance, EC 12.4 8.52 7.8 2.97 10.2 5.94 10.3 6.51 
 
E+M, 3 weeks of intense agility exercise program plus two years of exercise maintenance   
E, 3 weeks of intense agility exercise program only followed by assessments for 2 years  
C, no exercise only an assessment every three months for 2 years     
BMI, body mass index         
PD, Parkinsons's disease         
MDS-UPDRS M-EDL, Movement Disorders Society-Unified Parkinson's Disease  
   Rating Scale - Motor Experiences of Daily Living     
PDQ-39, Parkinson's Disease Questionnaire     
BDI, Beck depression inventory (0 to 20, lower value less depression)   
SE ADL, Schwab & England Activities of Daily Living Scale (Parkinson's Disease) 
    (0 to 100, 100 denoting no mobility disability)      
EQ-5D, EuroQol five dimensions questionnaire, VAS: visual analogue scale  
TUG, timed up and go tests (lower value denotes better mobility)   
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COP, center of pressure        
EO, eyes open         
EC, eyes closed         
*, not normally distributed        
**, baseline difference between groups, p<0.05     
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Table 2. Changes in primary and secondary outcome measures after the high-intensity agility program administered daily for 3 weeks 
and the high-intensity maintenance program administered 3 times per week for 2 years. 
  Exercise, weeks Followup, months 
  0 3 3 6 12 18 24 
Variable Group Mean ±SD Mean ±SD Mean ±SD Mean ±SD Mean ±SD Mean ±SD Mean ±SD 
Mass. Kg* E+M 75.9 ±11.46 - - - 74.6 ±10.12 - 74.7 ±9.38 
  E 73.8 ±7.31 - - - 73.3 ±6.25 - 74.3 ±6.35 
  C 79.4 ±11.55 - - - 76.7 ±8.88 - 75.4 ±8.08 
Leva-Dopa 
equivalent, E+M 774.2 ±381.49 - - 
779.2 
±378.10 
877.3 
±395.00 
858.6 
±427.09 866.5 ±438.59 
   mg/day E 912.6 ±380.10 - - 
960.9 
±367.39 
951.7 
±363.78 
977.1 
±385.48 992.5 ±394.68 
  C 884.8 ±331.97 - - 
884.8 
±331.97 
895.4 
±330.61 
918.6 
±300.33 1006.5 ±375.55 
MDS-UPDRS M-
EDL* E+M 19.4 ±6.28 13.1 ±3.67 9.6 ±2.48 9.4 ±2.19 10.0 ±2.20 9.6 ±2.03 9.5 ±1.47 
  E 19.1 ±4.54 10.6 ±3.28 15.1 ±2.63 17.4 ±2.94 19.1 ±2.51 19.4 ±2.44 18.9 ±2.15 
  C 18.9 ±7.94 18.6 ±7.56 20.1 ±7.04 19.4 ±6.24 22.8 ±6.46 21.1 ±4.43 21.9 ±3.54 
PDQ-39* E+M 49.9 ±16.61 37.1 ±13.15 35.9 ±11.74 35.4 ±10.91 35.3 ±10.17 35.5 ±9.59 34.8 ±10.01 
  E 49.3 ±9.65 35.5 ±9.43 36.1 ±9.52 40.5 ±9.20 42.0 ±8.48 45.9 ±8.11 50.1 ± 6.41 
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  C 39.6 ±18.27 40.8 ±16.79 43.3 ±15.45 44.8 ±13.42 47.1 ±13.70 
48.9 
±12.71 59.2 ±25.57 
Beck Depression 
Index E+M 19.4 ±5.73 16.4 ±4.79 16.4 ±4.79 15.3 ±4.35 15.9 ±4.58 15.5 ±5.04 13.9 ±4.06 
  E 14.5 ±3.53 10.9 ±3.63 13.9 ±3.56 12.2 ±3.81 14.8 ±3.11 13.5 ±2.47 15.5 ±1.81 
  C 15.3 ±10.42 15.3 ±9.48 15.3 ±10.38 15.2 ±9.29 16.0 ±9.27 18.5 ±7.51 20.7 ±5.86 
Schwab & England 
ADL. E+M 70.6 ±17.65 78.3 ±12.95 79.4 ±11.62 81.1 ±10.23 81.1 ±9.00 81.1 ±9.00 81.1 ±9.00 
     ADL, %*, ** E 66.2 ±9.61 78.5 ±6.89 76.9 ±7.51 72.3 ±9.27 68.5 ±5.55 68.5 ±8.01 66.2 ±6.50 
  C 72.0 ±18.97 71.3 ±18.47 71.3 ±18.47 70.0 ±16.90 68.7 ±15.98 
68.7 
±15.98 67.2 ±14.86 
EuroQol, Visual E+M 65.3±13.66 74.7 ±9.77 74.7 ±9.77 74.7 ±9.77 77.2 ±8.26 76.7 ±8.40 76.1 ±9.16 
analog scale, mm* E 67.7 ±9.27 76.9 ±6.30 76.9 ±6.30 76.2 ±6.50 75.4 ±6.60 74.6 ±6.60 74.6 ±6.60 
  C 63.8 ±11.50 62.3 ±10.50 62.3 ±10.50 62.3 ±10.50 61.7 ±9.57 59.7 ±8.55 59.7 ±8.55 
EuroQol, Summed E+M 14.1 ±2.49 10.9 ±1.61 9.6 ±1.54 8.9 ±1.26 8.7 ±1.32 8.8 ±1.25 8.7 ±1.41 
     Scores of 5 Items* E 13.1 ±1.32 11.2 ±1.24 10.9 ±1.50 11.7 ±1.18 11.7 ±1.18 12.4 ±1.04 12.5 ±1.45 
  C 14.5 ±2.48 13.6 ±2.10 13.4 ±1.88 13.7 ±1.50 13.7 ±1.44 14.3 ±1.29 14.4 ±1.30 
Timed-up-and go, s* E+M 16.9 ±3.91 10.6 ±2.92 11.0 ±2.56 10.9 ±2.79 11.0 ±2.72 10.9 ±2.49 10.8 ±2.41 
  E 14.8 ±3.54 8.7   ±1.78 10.6 ±1.35 12.5 ±1.70 13.2 ±1.59 13.6 ±1.68 14.4 ±1.50 
  C 17.7 ±3.25 17.2 ±3.04 16.9 ±3.02 17.2 ±3.13 17.4 ±2.39 17.4 ±1.72 17.6 ±2.19 
COP path, mm                 
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   Wide stance: Eyes E+M 8.9 ±7.79 3.4 ±1.22 3.2 ±0.93 3.2 ±0.94 3.2 ±0.97 3.2 ±0.98 3.2 ±1.07 
      Open* E 6.8 ±6.23 3.7 ±1.00 4.3 ±0.71 5.3 ±0.84 6.1 ±0.93 7.1 ±0.95 7.8 ±1.02 
  C 6.4 ±3.51 6.0 ±5.90 7.1 ±4.35 7.5 ±4.45 8.0 ±3.63 8.8 ±4.49 9.5 ±4.88 
   Wide stance: Eyes E+M 8.9 ±5.31 4.4 ±2.02 3.7 ±1.44 3.8 ±0.99 3.8 ±1.03 3.5 ±0.81 3.1 ±0.80 
     Closed* E 7.1 ±2.52 3.9 ±1.57 5.4 ±1.25 5.9 ±1.10 6.0 ±1.07 6.5 ±1.02 7.8 ±1.54 
  C 6.7 ±4.28 6.6 ±4.64 7.1 ±2.98 7.9 ±2.96 8.6 ±3.60 8.0 ±2.87 9.9 ±3.84 
   Narrow stance: Eyes E+M 10.3 ±5.82 4.1 ±1.55 3.9 ±0.80 3.4 ±0.63 4.1 ±1.08 4.3 ±0.74 3.9 ±0.91 
     Open* E 7.8 ±3.90 5.8 ±2.78 5.8 ±1.41 5.9 ±1.28 6.4 ±1.80 6.9 ±1.26 6.9 ±1.43 
  C 7.6 ±3.78 6.8 ±3.62 7.5 ±2.50 6.8 ±2.40 7.5 ±1.81 8.1 ±2.16 8.0 ±2.05 
   Narrow stance: Eyes E+M 12.1 ±8.68 5.3 ±2.46 4.5 ±0.76 4.4 ±0.78 4.7 ±1.07 4.6 ±0.70 4.0 ±0.53 
     Closed* E 8.3 ±2.63 5.2 ±2.07 6.2 ±1.31 6.4 ±1.56 6.5 ±2.18 6.5 ±0.99 6.5 ±1.02 
  C 9.2 ±5.25 8.6 ±4.28 8.5 ±2.67 8.3 ±2.24 9.2 ±3.47 8.9 ±2.60 9.8 ±2.91 
 
E+M (n=18), 3 weeks of intense agility exercise program plus two years of exercise maintenance  
E (n=13), 3 weeks of intense agility exercise program only followed by an assessment every three months for 2 years 
C  (n=15), no exercise, only an assessment every three months for 2 years     
MDS-UPDRS M-EDL, Movement Disorders Society-Unified Parkinson's Disease Rating Scale - Motor Experiences of Daily Living 
PDQ-39, Parkinson's Disease Questionnaire      
Beck depression inventory (0 to 20. lower value less depression)     
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Schwab & England Activities of Daily Living Scale (Parkinson's Disease) (0 to 100. 100 denoting no mobility disability) 
Timed up and go tests (lower value denotes better mobility)      
COP. center of pressure         
*, Group by Time interaction,  p<0.001       
**, Not normally distributed, analysis on logged transformed data  
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Table 3. Baseline comparisons between patients who died and those who completed the 2-year 
program. 
 
Completed, n = 46, 
17M  
Deceased, n = 9, 
6M t test 
Variable Mean   ±SD Mean  ±SD p value 
Age, y 67.5 3.86 67.9 3.14 0.778 
Height, cm 173.8 5.79 172.3 5.70 0.494 
Mass, kg 76.4 10.51 74.0 8.66 0.517 
BMI, kg·m·-2 25.2 2.51 24.9 2.26 0.696 
Hoehn - Yahr stage 2.4 0.49 2.4 0.53 0.771 
L-Dopa equivalent, 
mg/day 850.1 362.13 873.5 375.52 0.870 
PD years 6.6 2.34 8.1 2.67 0.082 
MDS-UPDRS M-EDL 18.0 5.91 25.1 5.78 0.002 
PDQ-39 sum score 46.4 15.99 8.9 2.32 0.001 
BDI 16.7 7.37 20.8 8.20 0.141 
SE ADL, %* 69.8 16.12 61.1 7.82 0.123 
EQ-5D VAS, mm 65.5 11.70 57.2 9.39 0.052 
EQ-5D sum score 14.0 2.25 14.9 2.67 0.275 
TUG, s 16.6 3.72 19.5 4.79 0.046 
COP path, mm          
   Wide stance, EO 7.5 6.20 7.3 4.92 0.950 
   Wide stance, EC 7.7 4.36 8.6 4.56 0.549 
   Narrow stance, EO 8.7 4.78 9.2 5.32 0.803 
   Narrow stance, EC 10.1 6.46 11.2 7.16 0.651 
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BMI, body mass index 
PD, Parkinsons's disease 
MDS-UPDRS M-EDL, Movement Disorders Society-Unified Parkinson's Disease Rating Scale      
   - Motor Experiences of Daily Living 
PDQ-39, Parkinson's Disease Questionnaire 
BDI, Beck depression inventory (0 to 20, lower value less depression) 
SE ADL, Schwab & England Activities of Daily Living Scale (Parkinson's Disease) (0 to 100, 
100 denoting no mobility disability) 
EQ-5D, EuroQol five dimensions questionnaire, VAS: visual analogue scale 
TUG, timed up and go tests (lower value denotes better mobility) 
COP, center of pressure 
EO, eyes open 
EC, eyes closed 
*, Not normally distributed 
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